Kyntra Bio, Inc. (KYNB)
8.02
+0.02
(+0.25%)
USD |
NASDAQ |
Aug 28, 16:00
7.975
-0.04
(-0.56%)
Pre-Market: 20:00
Kyntra Bio Enterprise Value : -36.84M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | -36.84M |
| August 27, 2026 | -36.93M |
| August 26, 2026 | -36.50M |
| August 25, 2026 | -36.52M |
| August 24, 2026 | -37.01M |
| August 21, 2026 | -38.87M |
| August 20, 2026 | -39.68M |
| August 19, 2026 | -40.37M |
| August 18, 2026 | -40.93M |
| August 17, 2026 | -41.74M |
| August 14, 2026 | -40.77M |
| August 13, 2026 | -40.81M |
| August 12, 2026 | -40.57M |
| August 11, 2026 | -40.69M |
| August 10, 2026 | -41.10M |
| August 07, 2026 | -39.88M |
| August 06, 2026 | -41.05M |
| August 05, 2026 | -41.01M |
| August 04, 2026 | -41.30M |
| August 03, 2026 | -41.95M |
| July 31, 2026 | -42.07M |
| July 30, 2026 | -41.82M |
| July 29, 2026 | -41.87M |
| July 28, 2026 | -41.08M |
| July 27, 2026 | -40.77M |
| Date | Value |
|---|---|
| July 24, 2026 | -40.85M |
| July 23, 2026 | -40.69M |
| July 22, 2026 | -40.10M |
| July 21, 2026 | -39.76M |
| July 20, 2026 | -40.81M |
| July 17, 2026 | -40.04M |
| July 16, 2026 | -39.40M |
| July 15, 2026 | -40.12M |
| July 14, 2026 | -39.68M |
| July 13, 2026 | -39.58M |
| July 10, 2026 | -38.52M |
| July 09, 2026 | -39.68M |
| July 08, 2026 | -38.99M |
| July 07, 2026 | -38.79M |
| July 06, 2026 | -39.96M |
| July 02, 2026 | -38.42M |
| July 01, 2026 | -38.75M |
| June 30, 2026 | -38.75M |
| June 29, 2026 | -3.883M |
| June 26, 2026 | -4.167M |
| June 25, 2026 | -5.381M |
| June 24, 2026 | -5.381M |
| June 23, 2026 | -5.260M |
| June 22, 2026 | -5.624M |
| June 18, 2026 | -6.353M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vericel Corp. | 2.028B |
| Capricor Therapeutics, Inc. | 410.38M |
| ARS Pharmaceuticals, Inc. | 538.52M |
| ACADIA Pharmaceuticals, Inc. | 4.128B |
| Alnylam Pharmaceuticals, Inc. | 31.39B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 11.97M |
| Revenue (Quarterly) | -1.474M |
| Total Expenses (Quarterly) | -13.45M |
| EPS Diluted (Quarterly) | 2.958 |
| Profit Margin (Quarterly) | -812.3% |
| Earnings Yield | 402.8% |
| Normalized Earnings Yield | 417.17 |